LENTIVIRAL VECTOR FOR GENE TRANSFER TO HEMATOPOIETIC STEM CELLS

用于基因转移至造血干细胞的慢病毒载体

• 批准号: 7715576
• 负责人: Donald B Kohn
• 金额: $ 10.84万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-01 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7715576
• 关键词: Autologous; Behavior Therapy; Bone Marrow Transplantation; Busulfan; Computer Retrieval of Information on Scientific Projects Database; Funding; Gene Transfer; Grant; Hematopoietic stem cells; Human; Institution; Lentivirus Vector; Research; Research Personnel; Resources; Source; Stem cells; Transplantation; United States National Institutes of Health; conditioning; cytotoxic

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: These studies focus on conditioning therapy (busulfan) for transplant of autologous transduced hematopoietic stem cells. Busulfan produces a specific loss of early stem cells and has been used as a stem cell cytotoxic conditioning agent prior to bone marrow transplantation in humans.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 目的：这些研究着重于调节疗法（Busulfan），用于自体转导造血干细胞的移植。 Busulfan产生早期干细胞的特异性丧失，并在人类进行骨髓移植之前已被用作干细胞细胞毒性调节剂。